West Pharma’s stock tanks 33% to lead S&P 500 decliners as guidance misses by a wide margin - MarketWatch
1. WST stock dropped 33% after disappointing 2025 guidance. 2. 2025 earnings forecast of $6-$6.20 is below $7.34 consensus. 3. West Pharma is exiting partnerships due to unachievable financial thresholds. 4. Growth expected in GLP-1 drug space despite current setbacks. 5. Stock has declined 48% over the last 12 months.